Today before the opening bell, TNI BioTech announced that the company has taken a major step forward with the signing of a Memorandum of Agreement with GB Oncology and Imaging Group LTD. ("GB") to equip and operate oncology and infectious diseases clinics in Equatorial Guinea.
Cancer is now one of the leading causes of death in developing countries. In fact, there are more deaths in the world from cancer than from HIV/AIDS, tuberculosis, and malaria combined. Leveraging the assistance of the Equatorial Guinea government, the two companies aim to provide better access and public awareness for the prevention, diagnoses, and treatment of cancer and other infectious diseases.
The chosen location for the first clinic is the capital city of Malabo. This clinic would serve as the central hub for general health care clinics throughout Equatorial Guinea and the surrounding countries. Utilizing cutting-edge treatment options, the partnership aims to deliver safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives. TNI BioTech will support the clinics with its patented therapies designed to boost patients' immune systems and improve quality of life.
"This partnership is the first step in many that will allow TNIB and GB to begin to deliver quality care not only to the people of Equatorial Guinea but hopefully throughout Africa," stated Dr. Herndon of TNI BioTech. "The need for quality care is critical because today advanced cancer treatment is available in only 23 of Africa's 53 countries, reaching less than 5% of the (total African) population."
To learn more about the company and its portfolio of immunotherapy technologies, visit www.tnibiotech.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html